NCT07000747Recruiting
Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients
Source: ClinicalTrials.gov · Last updated 3 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Dengue virus (DENV) belongs to the genus of Flavivirus transmitted by the mosquito Aedes aegypti and is responsible for an infectious disease associated with different forms and severities such as dengue hemorrhagic fever or shock syndrome. Several recent reports have shown that sickle cell patients exhibited an increased risk of developing severe forms of dengue episodes compared to non-sickle cell subjects. Furthermore, among major sickle cell syndromes, these studies suggest that SC patients are at the highest risk of death during these infectious episodes although this sickle cell syndrome is generally associated with a more moderate expression of sickle cell disease. However, the mechanisms involved remain unknown to date. The aim of the present study is to identify the molecular and cellular basis of this increased severity of dengue in SC patients. We hypothesize an exacerbation during DENV infection of the inflammatory response in SC patients compared to SS patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 130 (estimated)
- First submitted
- 21 May 2025
- Start date
- 24 Jun 2024
- Primary completion date
- 24 Jun 2026
- Lead sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
- Diseases
- Sickle cell disease
- NCT number
- NCT07000747
What you commit to
- Study type: Observational
- Planned participants: 130
- From 24 Jun 2024 to the primary completion date, 24 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- patients with SS or SC SCD or controls with hemoglobin AA
- diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
Age
- patients older than 6 years and younger than 25 at inclusion
Other
- clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months)
- patients followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe-à-Pitre)
- patients or legal representatives of minors who will provide written informed consent in accordance with the Declaration of Helsinki
- patients affiliated to national social security
- the control group (AA subjects) will be recruited among volunteers recruited by posters
Who the study is looking for
- patients with SS or SC SCD or controls with hemoglobin AA
- diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
- patients older than 6 years and younger than 25 at inclusion
- clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months)
- patients followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe-à-Pitre)
- patients or legal representatives of minors who will provide written informed consent in accordance with the Declaration of Helsinki
- patients affiliated to national social security
- the control group (AA subjects) will be recruited among volunteers recruited by posters
Age in the registry: 6 years to 25 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de la Guadeloupe Coordinator of this site? Confirm its status | Pointe-à-Pitre | Guadeloupe | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.